Can-Fite Biopharma Balance Sheet - Annual (NYSEMKT:CANF)

Add to My Stocks
$1.33 $0.05 (3.91%) CANF stock closing price Sep 18, 2018 (Closing)

A thorough fundamental analysis involves using data from Can-Fite Biopharma balance sheet, apart from other financial statements, to value the business. Financial strength can be guaged by performing Can-Fite Biopharma stock analysis and by analyzing the balance sheet. Annual results announcements include the release of all three financial statements, of which the balance sheet is one. Apart from analyzing Can-Fite Biopharma revenue Can-Fite Biopharma operating cash flow, one needs to check balance sheet items like cash, fixed assets and debt. The Can-Fite Biopharma balance sheet for 2017 shows cash on hand of $3.5M. The company has a debt to equity ratio of 0.

View latest 10 year balance sheet data to check Can-Fite Biopharma financial performance.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132011
Cash3.5M8.11M16.92M9.28M5.98M4.09M
Marketable Securities------
Receivables3.37M1.99M---1.05M
Inventory------
Raw Materials------
Work In Progress------
Finished Goods------
Notes Receivable------
Other Current Assets------
Total Current Assets
6.88M10.1M17.54M10.15M6.6M5.15M
Property Plant & Equipment------
Accumulated Depreciation------
Net Property Plant & Equipment
------
Investment & Advances------
Other Non-Current Assets------
Deferred Charges------
Intangibles------
Deposits & Other Assets------
Total Assets
7.85M10.17M17.6M10.2M6.65M5.23M
Notes Payable------
Accounts Payable1.42M2.18M1.55M---
Current Portion Long-Term Debt------
Current Portion Capital Leases------
Accrued Expenses------
Income Taxes Payable------
Other Current Liabilities---1.22M1.55M-
Total Current Liabilities
1.8M2.5M1.77M1.48M2.14M1.44M
Mortgages------
Deferred Taxes/Income-1.17M----
Convertible Debt------
Long-Term Debt------
Non-Current Capital Leases------
Other Long-Term Liabilities2.03M2.61M4.44M1.85M--
Total Liabilities
4.79M6.29M7.16M3.33M2.18M1.71M
Minority Interest------
Preferred Stock------
Common Stock Net2.4M1.83M1.8M1.39M1.16M-
Capital Surplus100.28M86.57M90.25M77.6M77.19M64.27M
Retained Earnings-105.91M-91.01M-82.74M-72.13M-80.78M-64.91M
Treasury Stock----1.04M-
Other Liabilities6.29M7.43M2.07M-7.94M3.42M
Shareholders Equity3.06M3.87M10.44M6.86M4.47M3.51M
Total Liabilities & Shareholders Equity7.85M10.17M17.6M10.2M6.65M5.23M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our Shire financial analysis

Most investors just check the Can-Fite Biopharma stock price, and Can-Fite Biopharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Can-Fite Biopharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like Can-Fite Biopharma owns and has monetary significance. CANF assets decreased from $10.17M in 2016 to $7.85M in 2017. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Can-Fite Biopharma is $4.79M. Shareholders' equity comes under liabilities as it is money the company owes the holders of CANF stock.

Can-Fite Biopharma Balance Sheet - Key Ratios

Current ratio
4.23
Debt to equity ratio
0
Asset turnover ratio
0.09
Receivables turnover
0.48
Price to book ratio
5.61